866-997-4948(US-Canada Toll Free)

MediPoint: Total Hip Replacement - South American Analysis and Market Forecasts

Published By :

GlobalData

Published Date : Jul 2013

Category :

Orthopedics

No. of Pages : 325 Pages


Osteoarthritis has become a global public health concern with no cure. It is the most common form of arthritis that is primarily due to wear and tear of the joints. With the aging global population, this is an indication that is growing rapidly with the hip being one of the most common joints afflicted. While the primary indication for total hip replacement (THR) is osteoporosis, the other major indications for THR are osteonecrosis and fractures to a lesser degree. As people live longer and with younger patients also receiving implants, the revision rates for primary hip replacements are also expected to rise. Primary hip replacement has become one of the most successful surgeries, with a variety of femoral and acetabular components available from a wide selection of manufacturers. This report focuses on the total primary hip replacement market along with primary revision market. The global hip replacement market has been estimated in this report which includes South America. The report provides unmet needs, future adoption and compounded annual growth rates (CAGR). GlobalDatas analysis shows that the hip replacement market has become a mature market where products have become commodities. The future of the market lays on the ability of manufacturers to provide implants at a very low cost while continuing to provide the same level of clinical efficacy. The product development need lies primarily in revising the resurfacing products articulating surface with new materials rather than developing new acetabular and femoral components. Additionally the major opportunity lies within the emerging markets which are the countries that have a higher CAGR and will provide the key for growth and grabbing market share.

Scope

  • An overview of Osteoarthritis, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. 
  • Annualized South American THR market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018. 
  • Investigation of current and future market competition for THR
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. 
  • Competitor assessment including device approval analysis and device sales forecasts. 
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. 
  • Analysis of unmet needs within the market and opportunities for future players. 
  • Technology trends evaluation to assess strength of pipeline. 
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines. 
  • Company profiles including business description, financial overview and SWOT analysis. 
  • Coverage of key market players. 
  • Strategic assessment of the THR sector through market impact analysis, future market scenario and company analysis. 
  • Direct quotes from Key Opinion Leaders (KOL) as well as Orthopedic Surgeon.

Reasons to buy

  • Understand the trends shaping and driving the South American THR Market. 
  • Realize device preferences of physicians who have performed the tests already. 
  • Access market sizing, forecasts and quantified growth opportunities in the South American THR market through 2018. 
  • Quantify candidate patient populations to better design product pricing & launch plans. 
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. 
  • Perform benchmarking analysis of growth opportunities against currently marketed products. 
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. 
  • Take a comprehensive look at the markets device pipeline and identify promising, paradigm-shifting products. 
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. 
  • Whats the next big thing in South American THR market landscape? Identify, understand and capitalize.
Table of Contents

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 16
1.2 List of Figures 26

2 Introduction 30
2.1 Catalyst 31

3 Disease Overview 32
3.1 Anatomy and Physiology 32
3.2 Pathophysiology 33
3.2.1 Overview 33
3.2.2 Osteoarthritis 33
3.2.3 Rheumatoid Arthritis 34
3.2.4 Post-traumatic Arthritis 35
3.2.5 Osteonecrosis 35
3.2.6 Injury 35
3.2.7 Bone Tumors 36
3.2.8 Other Diseases 36
3.3 Clinical Presentation 37
3.4 Clinical Outcomes 38
3.4.1 Overview 38
3.4.2 Conservative Therapy 40
3.4.3 Hip Arthroscopy 40
3.4.4 Hip Arthrodesis 41
3.4.5 Hemiarthroplasty (Partial) 42
3.4.6 Core Decompression 42
3.4.7 Hip Osteotomy 43
3.4.8 Resection Arthroplasty 43
3.4.9 Primary Total Hip Replacement 43
3.4.10 Revision Total Hip Replacement 46
3.4.11 Resurfacing Arthroplasty 46
3.4.12 Computer-Navigated Hip Replacement 47
3.5 Surgical Approaches 48
3.5.1 Anterolateral Approach 49
3.5.2 Posterior Approach 50
3.5.3 Direct Anterior Approach 50
3.5.4 Minimally Invasive Approaches 51
3.6 Epidemiology 51
3.6.1 South America 53
3.7 Economic Impact 54
3.7.1 South America 55

4 Competitive Assessment 56
4.1 Overview of Historical Designs 56
4.2 Marketed Products 57
4.2.1 Global Market Share 57
4.2.2 Primary Total Hip Replacement 57
4.2.3 Product Profiles by Company 58

5 Unmet Needs 201
5.1 Long-Term Clinical Data 201
5.2 Need for Continued Materials Research 201
5.3 Bearings 203
5.4 Refocus of Pipeline Products 204
5.5 Renewal of Resurfacing 205
5.6 Addressing the Learning Curve for Tier II Surgeons 206
5.7 Need for Cost Containment 208
5.8 Centralization 209
5.9 National Joint Registry 210

6 Pipeline Products 211
6.1 Overview 211
6.2 Primary Total Hip Pipeline Products 212
6.2.1 Exactech LPI Prime Hip System 212
6.2.2 EnduRo Bone-preserving Hip Stem 213
6.2.3 Deltamotion Acetabular Cup System 213
6.2.4 NovoSource Hip Implant 213

7 Industry Overview 214
7.1 Procedure Volumes 214
7.1.1 South America 215
7.2 Market Access 216
7.2.1 South America 216
7.3 Reimbursement Trends 217
7.3.1 South America 217
7.4 Regulatory Issues/Recalls 219
7.4.1 DePuy Hip Replacement Recall 219
7.4.2 Stryker Hip Replacement Recall 220
7.4.3 Smith & Nephew Recall: R3 Metal Liners of the R3 Acetabular System 220
7.4.4 Zimmer Durom Acetabular Component 220
7.4.5 Biomet Hip Replacement Complications 220
7.4.6 Wright Medical Conserve Hip Implant 221
7.4.7 The Corin Group Metal-on-Metal Hip Resurfacing 221
7.5 Mergers & Acquisitions / Key Partnerships 222
7.5.1 Medtronic Acquires China Kanghui Holdings 222
7.5.2 Tornier Acquires OrthoHelix Surgical Designs Inc. 222
7.5.3 DePuy Orthopaedics (Johnson & Johnson) and Synthes Inc. Merge 222
7.5.4 Italian Consortium 2IL Orthopaedics Ltd Acquires Corin Group 223
7.5.5 Zimmer Acquires Beijing Montagne Medical Device Co. Ltd. 223
7.5.6 Wright Medial Announces Agreement to Sell OrthoRecon Business to MicroPort Medical B.V. 223

8 Company Profiles 224
8.1 B. Braun 224
8.1.1 Overview 224
8.1.2 Portfolio Assessment 225
8.1.3 SWOT Analysis 225
8.2 Biomet Orthopedics 226
8.2.1 Overview 226
8.2.2 Portfolio Assessment 227
8.2.3 SWOT Analysis 230
8.3 Corentec Co. Ltd. 230
8.3.1 Overview 230
8.3.2 Portfolio Assessment 231
8.3.3 SWOT Analysis 231
8.4 Corin 232
8.4.1 Overview 232
8.4.2 Portfolio Assessment 233
8.4.3 SWOT Analysis 234
8.5 DePuy Synthes International 234
8.5.1 Overview 234
8.5.2 Portfolio Assessment 235
8.5.3 SWOT Analysis 237
8.6 Exactech 238
8.6.1 Overview 238
8.6.2 Portfolio Assessment 239
8.6.3 SWOT Analysis 241
8.7 Iconacy Orthopedic Implants LLC 241
8.7.1 Overview 241
8.7.2 Portfolio Assessment 242
8.7.3 SWOT Analysis 242
8.8 Implantcast GMBH 243
8.8.1 Overview 243
8.8.2 Portfolio Assessment 243
8.8.3 SWOT Analysis 245
8.9 JRI Orthopaedics 245
8.9.1 Overview 245
8.9.2 Portfolio Assessment 246
8.9.3 SWOT Analysis 247
8.10 Kyocera 247
8.10.1 Overview 247
8.10.2 Portfolio Assessment 248
8.10.3 SWOT Analysis 249
8.11 Limacorporate S.P.A 250
8.11.1 Overview 250
8.11.2 Portfolio Assessment 250
8.11.3 SWOT Analysis 252
8.12 Medacta 252
8.12.1 Overview 252
8.12.2 Portfolio Assessment 253
8.12.3 SWOT Analysis 254
8.13 Medtronic 254
8.13.1 Overview 254
8.13.2 Portfolio Assessment 255
8.13.3 SWOT Analysis 256
8.14 NovoSource Inc. 257
8.14.1 Overview 257
8.14.2 Portfolio Assessment 257
8.14.3 SWOT Analysis 258
8.15 Peter Brehm GMBH 258
8.15.1 Overview 258
8.15.2 Portfolio Assessment 259
8.15.3 SWOT Analysis 259
8.16 Serf Dedienne Sante 260
8.16.1 Overview 260
8.16.2 Portfolio Assessment 261
8.16.3 SWOT Analysis 262
8.17 Smith & Nephew 262
8.17.1 Overview 262
8.17.2 Portfolio Assessment 263
8.17.3 SWOT Analysis 265
8.18 Stelkast 265
8.18.1 Overview 265
8.18.2 Portfolio Assessment 266
8.18.3 SWOT Analysis 266
8.19 Stryker 267
8.19.1 Overview 267
8.19.2 Portfolio Assessment 268
8.19.3 SWOT Analysis 269
8.20 Tianjin Zhengtian Medical Instrument Co., Ltd. 270
8.20.1 Overview 270
8.20.2 Portfolio Assessment 270
8.20.3 SWOT Analysis 271
8.21 Tornier N.V. 271
8.21.1 Overview 271
8.21.2 Portfolio Assessment 272
8.21.3 SWOT Analysis 274
8.22 Wright Medical 274
8.22.1 Overview 274
8.22.2 Portfolio Assessment 275
8.22.3 SWOT Analysis 277
8.23 United Orthopedic Corporation 278
8.23.1 Overview 278
8.23.2 Portfolio Assessment 279
8.23.3 SWOT Analysis 279
8.24 Zimmer Holdings Inc. 280
8.24.1 Overview 280
8.24.2 Portfolio Assessment 281
8.24.3 SWOT Analysis 283
8.25 Other Companies 284

9 Market Drivers, Opportunities and Barriers 285
9.1 Market Drivers 285
9.1.1 Prevalence Rise 285
9.1.2 Expanding Indications 287
9.1.3 Availability and Lack of Long-Term Clinical Data 288
9.1.4 Fracture Incidence 288
9.1.5 Patient Demand and Awareness 288
9.2 Opportunities 289
9.2.1 Revision Surgery 289
9.2.2 Emerging Markets 289
9.2.3 Continued Materials Research 290
9.2.4 Corporate Promotions and Teaching Seminars 291
9.2.5 Advancement towards Cost Reduction 291
9.3 Market Barriers 292
9.3.1 Market Barriers 292

10 Country Outlooks & Forecasts 296
10.1 Brazil Market Analysis 296

11 Appendix 298
11.1 Abbreviations 298
11.2 Bibliography 299
11.3 Report Methodology 316
11.3.1 Overview 316
11.3.2 Coverage 316
11.3.3 Secondary Research 317
11.3.4 Forecasting Methodology 318
11.3.5 Primary Research – Key Opinion Leader Interviews 319
11.3.6 Expert Panel Validation 319
11.4 Physicians and Specialists Included in this Study 320
11.4.1 Dr. Alessandro Aprato 320
11.4.2 Dr. Fran Channa 320
11.4.3 Joseph Daniel FRCS MS (Orth) 320
11.4.4 Dr. Alejandro Gonzalez Della Valle 320
11.4.5 Dr. Moussa Hamadouche 320
11.4.6 Dr. Sheng-Li Huang and Xi-Jing He 320
11.4.7 Dr. Ayumi Kaneuji 320
11.4.8 Dr. Yuichi Mitani 320
11.4.9 Dr. Ning Lu 321
11.4.10 Dr. Deepak Saini 321
11.4.11 Dr. Lafayette Lage 321
11.4.12 Dr. Christoph Zilkens 321
11.5 About the Authors 322
11.5.1 Analysts 322
11.5.2 Global Head of Healthcare 323
11.6 About MediPoint 324
11.7 About GlobalData 324
11.8 Disclaimer 324

List of Table


Table 1: Clinical Symptoms and Descriptions 37
Table 2: Advantages and Disadvantages of Hip Resurfacing 47
Table 3: Surgical Approaches Comparison 48
Table 4: South American Prevalence of Osteoarthritis, 20102019 52
Table 5: Direct and Indirect Costs of Arthritis 54
Table 6: Bicontact Universal Hip System (B. Braun) 60
Table 7: Clinical Studies Bicontact Universal Hip System (B. Braun) 60
Table 8: SWOT Bicontact Universal Hip System 61
Table 9: Excia Hip Stem (B. Braun) 63
Table 10: Clinical Studies Excia Hip Stem (B. Braun) 64
Table 11: SWOT Excia Hip Stem 64
Table 12: Metha Short Hip Stem (B. Braun) 66
Table 13: Clinical Studies Metha Short Hip Stem (B. Braun) 67
Table 14: SWOT Metha Short Hip Stem 67
Table 15: TRJ Cementless Hip Endoprosthesis System (B. Braun) 69
Table 16: SWOT TRJ Cementless Hip Endoprosthesis System 70
Table 17: Plasmacup SC Acetabular Cup (B. Braun) 71
Table 18: Balance Femoral Component (Biomet) 73
Table 19: Clinical Studies Balance Femoral Component (Biomet) 73
Table 20: SWOT Balance Femoral Component 74
Table 21: Bi-Metric Femoral Components (Biomet) 75
Table 22: Clinical Studies Bi-Metric Femoral Components (Biomet) 75
Table 23: SWOT Bi-Metric Femoral Components 76
Table 24: Bio-Moore II Hip System (Biomet) 77
Table 25: Clinical Studies Bio-Moore II Hip System (Biomet) 77
Table 26: SWOT Bio-Moore II Hip System 78
Table 27: Generation 4 Polished Hip System (Biomet) 79
Table 28: SWOT Generation 4 Polished Hip System 79
Table 29: Integral Porous Primary Hip System (Biomet) 81
Table 30: Clinical Studies Integral Porous Hip System (Biomet) 81
Table 31: SWOT Integral Porous Hip System Femoral Components 82
Table 32: Mallory Femoral Component (Biomet) 83
Table 33: Clinical Studies Mallory Femoral Component (Biomet) 83
Table 34: SWOT Mallory Femoral Component 84
Table 35: Progressive Total Hip System (Biomet) 85
Table 36: SWOT Progressive Total Hip System 85
Table 37: Rx 90 Smooth Primary Femoral Component (Biomet) 87
Table 38: SWOT Rx 90 Smooth Primary Femoral Component 87
Table 39: Stanmore Hip System (Biomet) 88
Table 40: Clinical Studies Stanmore Hip System (Biomet) 89
Table 41: SWOT Stanmore Hip System 89
Table 42: Taperloc and Balance Microplasty Hip Stems (Biomet) 90
Table 43: Clinical Studies Taperloc and Balance Microplasty Hip Stems (Biomet) 91
Table 44: SWOT Taperloc and Balance Microplasty Hip Stems 91
Table 45: Acetabular Systems (Biomet) 92
Table 46: Bencox Stems (Corentec Co. Ltd) 94
Table 47: Clinical Studies Bencox Stems (Corentec Co. Ltd) 94
Table 48: SWOT Bencox Stems 95
Table 49: Bencox Acetabular Systems (Corentec Co. Ltd.) 96
Table 50: MetaFix (Corin) 97
Table 51: SWOT MetaFix 97
Table 52: MiniHip (Corin) 99
Table 53: SWOT MiniHip 99
Table 54: MRP-Titan (Corin) 101
Table 55: SWOT MRP-Titan 101
Table 56: TaperFit (Corin) 103
Table 57: SWOT TaperFit 103
Table 58: Trinity Acetabular System (Corin) 105
Table 59: Cenator Acetabular Cup (Corin) 106
Table 60: Cementless Systems (DePuy Synthes) 108
Table 61: Clinical Studies Cementless Systems (DePuy Synthes) 108
Table 62: SWOT DePuy Synthes Cementless Systems 109
Table 63: Cemented Systems (DePuy Synthes) 110
Table 64: Clinical Studies Cemented Systems (DePuy Synthes) 110
Table 65: SWOT DePuy Synthes Cemented Systems 110
Table 66: DePuy Synthes Acetabular Systems (DePuy Synthes) 112
Table 67: AcuMatch Femoral Stems (Exactech) 113
Table 68: Clinical Studies AcuMatch Femoral Stems (Exactech) 114
Table 69: SWOT AcuMatch Femoral Stems 114
Table 70: Novation Femoral Stems (Exactech) 116
Table 71: Clinical Studies Novation Femoral Stems (Exactech) 116
Table 72: SWOT Novation Femoral Stems 117
Table 73: Exactech Acetabular Systems (Exactech) 117
Table 74: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 119
Table 75: SWOT i-Hip Total Hip Implant 119
Table 76: EcoFit Femoral Stem (Implantcast GMBH) 121
Table 77: Aida Short Femoral Stem (Implantcast GMBH) 122
Table 78: AJS Hip System (Implantcast GMBH) 123
Table 79: DiaLoc Hip Stem (Implantcast GMBH) 124
Table 80: LOAD SHIFT Hip Stem (Implantcast GMBH) 125
Table 81: Ceraco Hip Stem (Implantcast GMBH) 126
Table 82: IC Straight Stem Type I and Type II (Implantcast GMBH) 127
Table 83: Bicana Hip Stem (Implantcast GMBH) 128
Table 84: SWOT Implantcast GMBH Femoral Stems 129
Table 85: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 130
Table 86: Aeon Hip System (JRI Orthopaedics) 131
Table 87: SWOT Aeon Hip System 131
Table 88: Furlong Hip System and Evolution System (JRI Orthopaedics) 132
Table 89: Clinical Studies Furlong Hip System (JRI Orthopaedics) 133
Table 90: SWOT Furlong Hip System and Evolution System 133
Table 91: Limacorporate Cementless Femoral Stems (Limacorporate SPA) 135
Table 92: SWOT Limacorporate Cementless Femoral Stems 135
Table 93: Cemented and Cementless Stems (Limacorporate SPA) 136
Table 94: SWOT Cemented and Cementless Stems (Limacorporate SPA) 137
Table 95: Limacorporate Acetabular Systems 137
Table 96: Cemented and Cementless Stems (Medacta) 139
Table 97: SWOT Medacta Stems 139
Table 98: Acetabular Cups and Femoral Heads (Medacta) 140
Table 99: Helicon Hip System (TGM Medical, wholly owned by Medtronic) 141
Table 100: SWOT Helicon Hip System 142
Table 101: Vektor Titan and Vektor CoCr (Peter Brehm GMBH) 144
Table 102: Clinical Studies Peter Brehm Stems (Peter Brehm GMBH) 144
Table 103: SWOT Peter Brehm Products 145
Table 104: Libra and Sagittal EVL (Serf Dedienne Sant

List of Chart


Figure 1: Anatomy of the Hip 32
Figure 2: Treatment Paradigm for Hip Osteoarthritis 38
Figure 3: Treatment Paradigm for Hip Fractures 39
Figure 4: Hip Arthrodesis 41
Figure 5: Partial Hip Arthroplasty and Total Hip Arthroplasty 44
Figure 6: Surgical Approach Used by Orthopedic Surgeons Globally 48
Figure 7: Surgical Approach Used by Orthopedic Surgeons in North America 49
Figure 8: Population with Osteoarthritis in South America, 20102019 53
Figure 9: Global Market Share for Reconstructive Products, 2012 57
Figure 10: Bicontact Universal Hip System (B. Braun) 59
Figure 11: Excia Hip Stem (B. Braun) 62
Figure 12: Metha Short Hip Stem (B. Braun) 65
Figure 13: TRJ Cementless Hip Endoprosthesis System (B. Braun) 68
Figure 14: Plasmacup SC Acetabular Cup (B. Braun) 70
Figure 15: Balance Femoral Component (Biomet) 72
Figure 16: Bi-Metric Femoral Components (Biomet) 74
Figure 17: Bio-Moore II Hip System (Biomet) 76
Figure 18: Generation 4 Polished Hip System (Biomet) 78
Figure 19: Integral Porous Primary Hip System (Biomet) 80
Figure 20: Mallory Femoral Component (Biomet) 82
Figure 21: Progressive Total Hip System (Biomet) 84
Figure 22: Rx 90 Smooth Primary Femoral Component (Biomet) 86
Figure 23: Stanmore Hip System (Biomet) 88
Figure 24: Taperloc and Balance Microplasty Hip Stems (Biomet) 90
Figure 25: Bencox Stems (Corentec Co. Ltd) 93
Figure 26: Bencox Acetabular Systems (Corentec Co. Ltd.) 95
Figure 27: MetaFix (Corin) 96
Figure 28: MiniHip (Corin) 98
Figure 29: MRP-Titan (Corin) 100
Figure 30: TaperFit (Corin) 102
Figure 31: Trinity Acetabular System (Corin) 104
Figure 32: Cenator Acetabular Cup (Corin) 106
Figure 33: Cementless Systems (DePuy Synthes) 107
Figure 34: Cemented Systems (DePuy Synthes) 109
Figure 35: DePuy Acetabular Systems (DePuy Synthes) 111
Figure 36: AcuMatch Femoral Stems (Exactech) 113
Figure 37: Novation Femoral Stems (Exactech) 115
Figure 38: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 118
Figure 39: EcoFit Femoral Stem (Implantcast GMBH) 120
Figure 40: Aida Short Femoral Stem (Implantcast GMBH) 122
Figure 41: AJS Hip System (Implantcast GMBH) 123
Figure 42: DiaLoc Hip Stem (Implantcast GMBH) 124
Figure 43: LOAD SHIFT Hip Stem (Implantcast GMBH) 125
Figure 44: Ceraco Hip Stem (Implantcast GMBH) 126
Figure 45: IC Straight Stem Type I and Type II (Implantcast GMBH) 127
Figure 46: Bicana Hip Stem (Implantcast GMBH) 128
Figure 47: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 129
Figure 48: Aeon Hip System (JRI Orthopaedics) 130
Figure 49: Furlong Hip System and Evolution System (JRI Orthopaedics) 132
Figure 50: Cemented and Cementless Stems (Limacorporate SPA) 136
Figure 51: Cemented and Cementless Stems (Medacta) 138
Figure 52: Helicon Hip System (TGM Medical wholly owned by Medtronic) 141
Figure 53: Vektor-Titan and Vektor-CoCr (Peter Brehm GMBH) 143
Figure 54: Libra and Sagitta EVL (Serf Dedienne Sant

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *